Skip to content
MarketScale
‹ Back to IndustriesHealthcare

New Algorithm Uses CT Data to Create 3D Map and Better Assess Osteoarthritis

Engineers, radiologists and physicians based in the UK have developed a new technique for improving clinical imaging. It uses an algorithm to create a detailed three-dimensional map of a patient’s joint using computed tomography (CT) data. The team, led by co-author Tom Turmezei, Ph.D. of Cambridge University, recently reported on their breakthrough with a journal article titled…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Engineers, radiologists and physicians based in the UK have developed a new technique for improving clinical imaging. It uses an algorithm to create a detailed three-dimensional map of a patient’s joint using computed tomography (CT) data. The team, led by co-author Tom Turmezei, Ph.D. of Cambridge University, recently reported on their breakthrough with a journal article titled “A new quantitative 3D approach to imaging of structural joint disease,” which appeared in the June 2018 edition of Scientific Reports.

The team knew that the ability to assess OA with 2D radiographs was not good enough to detect subtle changes that could have important implications for patients, doctors, and researchers. To meet this challenge, they worked to develop a new algorithm for the structural assessment of joints including hips, knees and ankles in 3D. Their recent technical validation study showed the technique was successful.

The algorithm maps joint space width to the nearest tenth of a millimeter. Mapping joint space width in 3D from clinical CT data has the potential to enhance understanding of osteoarthritis and how patients progress to joint failure—leading to better and earlier interventions.

Early Detection Gives Osteoarthritis Patients More Options

The 3D mapping technique has the potential to be more than twice as sensitive as radiographs in detecting small changes in joint space widths. Using the algorithm, clinicians will be able to use CT scans to map a marker of osteoarthritis across a joint. Why does it matter? Because early detection leads to earlier treatment. Doctors could identify patients with disease earlier than the current gold standard, allowing important interventions to be started before the joint fails. Patients will have the opportunity to try lifestyle changes and physiotherapy instead of immediately facing surgery.

All clinical CT imaging was performed on a 64-slice Siemens Definition AS system.

“It will be an important next step to use JSM to investigate whether differences in positioning and load-bearing have any effect on joint space width in 3D,” the authors wrote. “A straightforward solution for prospective studies would be to perform knee and ankle CT in a standing position (as used in clinical practice), and to standardise supine hip positioning by strapping feet together.”

Evaluating New Therapies

In addition, the new 3D method will likely allow researchers to determine whether new therapies in development are effective in a realistic timescale for clinical trials. This is something that has not been possible using radiographs.

CurveBeam designs and manufactures Cone Beam CT imaging equipment for the orthopedic and podiatric specialties. Bilateral, weight bearing scans of the foot and ankle give physicians the information necessary to assess the biomechanical spatial relationships and alignment of the lower extremities.

To learn about a recent grant awarded to the University of Kansas to study joint space biomarkers via weight bearing CT, click here.

Read more at curvebeam.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Scan.com’s $220M round makes imaging an API contract for plans and employers

Scan.com’s $220M round makes imaging an API contract for plans and employers

Scan.com closed $220 million in equity and debt. It’s expanding its U.S. imaging network plus API-based scheduling and results delivery. For health plans and employers, imaging is starting to look like a platform procurement and integration decision, not a directory problem.

  • 01If imaging access is bought via an API, the real spec becomes integration depth: two-way scheduling plus results routing into the EMR, according to Business Wire.
  • 02Scan.com’s mix of $90M equity and $130M debt earmarked for M&A and working capital points to a fast-changing imaging provider network, which can help access but demands discipline in contracting and integration testing.
  • 03The same week’s funding news for Elucid ($55M) suggests AI imaging vendors will keep pushing toward FDA-cleared workflow insertions, a different buying path than network-layer platforms.

Sep 4, 2026

MD&M West 2026 exhibitors pitch audit-ready, AI-ready device platforms

MD&M West 2026 exhibitors pitch audit-ready, AI-ready device platforms

MD&M West 2026 exhibitor messaging suggests compliance testing and AI-ready compute are becoming early decisions, not afterthoughts. Medical Economics described 2026 as a period shaped by rapid technological change, regulatory scrutiny and ongoing economic uncertainty. Medical Design & Outsourcing’s MD&M West 2026 preview points to exhibitors highlighting test equipment, contract manufacturing and other launch support services.

  • 01If a device roadmap includes AI features, the critical path shifts toward data and software evidence that regulators can audit, which means earlier lock-in of compute platforms and test plans, pulling verification and validation into supplier selection.
  • 02MD&M West exhibitor messaging suggests verification and validation capacity is becoming a procurement problem, with rentals and lab-ready gear positioned as a way to avoid booking delays and re-tests, according to Medical Design & Outsourcing.
  • 03With imaging and other new procedural and device concepts moving fast, manufacturing leaders should expect more frequent line-change decisions and component qualification work, as GE HealthCare's photon-counting CT CE mark reported by MedTech Dive and MDDI's New Technologies coverage illustrate.

Sep 3, 2026

Dr. Dana Rosencranz - Cancer Survivor and Chief Medical Physicist

Dr. Dana Rosencranz - Cancer Survivor and Chief Medical Physicist

Dr. Dana Rosencranz brings 23+ years of experience as chief medical physicist at Texas Oncology and personal insight as a breast cancer survivor, enabling her to guide patient support groups and advocate for accessible cancer care. She emphasizes AI's potential in auto-contouring and treatment planning while stressing the need for proper training, validation, and transparency before implementation.

  • 01Over 23 years at Texas Oncology integrating personal cancer survivor experience with clinical expertise to improve patient empathy and support group leadership
  • 02AI in oncology requires human oversight, validation, and transparency; auto-contouring and auto-planning must be combined with staff training and rigorous protocol testing before deployment
  • 03Texas Oncology prioritizes offering state-of-the-art cancer treatments closer to home, including for rural patients, to reduce travel and ensure consistent, personalized care

Sep 3, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512